Agenus downgraded by Robert W. Baird with a new price target
$AGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Robert W. Baird downgraded Agenus from Outperform to Neutral and set a new price target of $8.00 from $35.00 previously